Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression
Open accessAbstract
Despite advances in therapy, multiple myeloma remains incurable, with a high frequency of relapse. This suggests the need to identify additional factors that contribute to drug resistance. Our previous studies revealed that bone marrow adipocytes promote resistance to chemotherapy in myeloma through adipocyte-secreted adipokines, but the mechanism underlying this effect and the specific adipokines involved are not well understood. We proposed to determine the role of resistin, an adipokine that is secreted by adipocytes, in chemotherapy resistance in myeloma. We found that resistin abrogated chemotherapy-induced apoptosis in established myeloma cell lines and primary myeloma samples. Resistin inhibited chemotherapy-induced caspase cleavage through the NF-κB and PI3K/Akt pathways. Resistin also increased the expression and drug efflux function of ATP-binding cassette (ABC) transporters in myeloma cells through decreasing the expression of both DNA methyltransferases DNMT1 and DNMT3a and the methylation levels of ABC gene promoters. In vivo studies further demonstrated the protective effect of resistin in chemotherapy-induced apoptosis. Our study thus reveals a new biological function of resistin in the pathogenesis of myeloma, with the implication that targeting resistin could be a potential strategy to prevent or overcome multidrug resistance in myeloma.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Myeloma cells interact with BMSCs and the ECM, facilitating their growth and better survival and making them resistant to drugs.
“Because of the importance of BM in cell growth and its expansion in the progression of MM, researchers have depicted that myeloma cells interact with BMSCs and the ECM, facilitating their growth and better survival and making them resistant to drugs [239].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [239]
BMSCs activate NF-κB, PI3K/Akt, and MAPK signaling pathways, which in turn suppress caspase cleavage and apoptosis in myeloma cells caused by chemotherapy.
“Additionally, they activate the nuclear factor kappa B (NF-κB), phosphoinositide 3 kinase (PI3K)/Akt, and mitogen-activated protein kinase (MAPK) signaling pathways, which in turn suppresses caspase cleavage and apoptosis in myeloma cells caused by chemotherapy [233, 239].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [239]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143 · see citing works
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · see citing works
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755 · see citing works
Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases
Okano, M., Xie, S., & Li, E. (1998) · Nature Genetics · doi:10.1038/890 · Cited by 1,643 · see citing works
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932 · see citing works
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 732 · see citing works
Röllig, C., Knop, S. T., & Bornhäuser, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 610 · see citing works
Epigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 483 · see citing works
×Phosphorylation of Bax Ser184 by Akt Regulates Its Activity and Apoptosis in Neutrophils
Gardai, S. J., Hildeman, D. A., Frankel, S., Whitlock, B. B., Frasch, S. C., Borregaard, N., Marrack, P., Bratton, D. L., & Henson, P. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400063200 · Cited by 402 · see citing works
Görgün, G., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J. P., Raje, N. S., Munshi, N. C., Richardson, P. G. G., & Anderson, K. C. (2013) · Blood · doi:10.1182/blood-2012-08-448548 · Cited by 394 · see citing works
Bcl-2–family proteins and hematologic malignancies: history and future prospects
Reed, J. C. (2008) · Blood · doi:10.1182/blood-2007-09-078162 · Cited by 346 · see citing works
Robey, R. W., Medina-Pérez, W. Y., Nishiyama, K., Lahusen, T. J., Miyake, K., Litman, T., Senderowicz, A. M., Ross, D. D., & Bates, S. E. (2001) · PubMed · Cited by 341 · see citing works
Molecular pathogenesis of multiple myeloma and its premalignant precursor
Kuehl, W. M., & Bergsagel, P. L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61188 · Cited by 336 · see citing works
Zheng, Y., Cai, Z., Wang, S., Zhang, X., Qian, J., Hong, S., Li, H., Wang, M. L., Yang, J., & Yi, Q. (2009) · Blood · doi:10.1182/blood-2009-05-220285 · Cited by 309 · see citing works
Self-citationZhou, W. H., Yang, Y., Xia, J., Wang, H., Salama, M. E., Xiong, W., Xu, H., Shetty, S., Chen, T., Zeng, Z., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.001 · Cited by 290 · see citing works
Chauhan, D., Singh, A., Brahmandam, M., Carrasco, R. D., Bandi, M. L., Hideshima, T., Bianchi, G., Podar, K., Tai, Y., Mitsiades, C. S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.019 · Cited by 287 · see citing works
Resistin release by human adipose tissue explants in primary culture
Fain, J. N., Cheema, P. S., Bahouth, S. W., & Hiler, M. L. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02864-4 · Cited by 252 · see citing works
Bcl-2 family proteins as targets for anticancer drug design
Huang, Z. (2000) · Oncogene · doi:10.1038/sj.onc.1204087 · Cited by 201 · see citing works
ABCG2 expression, function, and promoter methylation in human multiple myeloma
Turner, J. G., Gump, J. L., Zhang, C., Cook, J. M., Marchion, D. C., Hazlehurst, L., Münster, P. N., Schell, M. J., Dalton, W. S., & Sullivan, D. M. (2006) · Blood · doi:10.1182/blood-2005-10-009084 · Cited by 189 · see citing works
Park, S., Shimizu, C., Shimoyama, T., Takeda, M., Ando, M., Kohno, T., Katsumata, N., Kang, Y., Nishio, K., & Fujiwara, Y. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9175-2 · Cited by 182 · see citing works
Liu, Z., Xu, J., He, J., Liu, H., Lin, P., Wan, X., Navone, N. M., Tong, Q., Kwak, L. W., Orlowski, R. Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6020 · Cited by 165 · see citing works
Self-citationBorel, F., Han, R., Visser, A., Petry, H., van Deventer, S. J. H., Jansen, P. L. M., & Konstantinova, P. S. (2011) · Hepatology · doi:10.1002/hep.24682 · Cited by 153 · see citing works
Wielinga, P. R., Hooijberg, J. H., Gunnarsdottir, S., Kathmann, I., Reid, G., Zelcer, N., van der Born, K., de Haas, M., van der Heijden, I., Kaspers, G. J. L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2810 · Cited by 139 · see citing works
Ding, X., Sun, G., Argaw, Y. G., Wong, J. O., Easwaran, S., & Montell, D. J. (2016) · eLife · doi:10.7554/elife.10936 · Cited by 128 · see citing works
Mohelníková-Duchoňová, B., Brynychová, V., Oliverius, M., Honsová, E., Kala, Z., Múčková, K., & Souček, P. (2013) · Pancreas · doi:10.1097/mpa.0b013e318279b861 · Cited by 111 · see citing works
Kim, H. J., Lee, Y., Won, E. H., Chang, I. H., Kim, T., Park, E. S., Kim, M. K., Kim, W., & Myung, S. C. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09813.x · Cited by 87 · see citing works
BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy
Lindqvist, L., & Vaux, D. L. (2014) · Autophagy · doi:10.4161/auto.29639 · Cited by 83 · see citing works
The role of resistin in colorectal cancer
Danese, E., Montagnana, M., Minicozzi, A. M., Bonafini, S., Ruzzenente, O., Gelati, M., Manzoni, G. D., Lippi, G., & Guidi, G. C. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.01.019 · Cited by 68 · see citing works
Resistin, an adipocytokine, offers protection against acute myocardial infarction
Gao, J., Chua, C. C., Chen, Z., Wang, H., Xu, X., Hamdy, R. C., McMullen, J. R., Shioi, T., Izumo, S., & Chua, B. H. L. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.08.009 · Cited by 67 · see citing works
Targeting the bone microenvironment in multiple myeloma
Roodman, G. D. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0154-7 · Cited by 47 · see citing works
Kuo, C.-H., Chen, K.-F., Chou, S., Huang, Y., Wu, C., Cheng, D.-E., Chen, Y., Yang, C., Hung, J., & Huang, M. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt281 · Cited by 46 · see citing works
Resistin protects against 6‐hydroxydopamine‐induced cell death in dopaminergic‐like MES23.5 cells
Lu, D., Chen, J.-H., Tan, T., Huang, C., Yeh, W., & Hsu, H. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24163 · Cited by 34 · see citing works
Nakano, H., Nakamura, Y., Soda, H., Kamikatahira, M., Uchida, K., Takasu, M., Kitazaki, T., Yamaguchi, H., Nakatomi, K., Yanagihara, K., et al. (2008) · Cancer · doi:10.1002/cncr.23285 · Cited by 32 · see citing works
Yang, J., He, J., Wang, J. R., Cao, Y., Ling, J., Qian, J., Lu, Y., Li, H., Zheng, Y., Lan, Y., et al. (2012) · Leukemia · doi:10.1038/leu.2012.71 · Cited by 31 · see citing works
Self-citationLiu, L., ZUO, L. F., & GUO, J. W. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.1949 · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bone Marrow Fat and Hematopoiesis
Wang, H., Leng, Y., & Gong, Y. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00694 · Cited by 115 · see citing works
Pine, G. M., Batugedara, H., & Nair, M. G. (2018) · Cytokine · doi:10.1016/j.cyto.2018.05.014 · Cited by 104 · see citing works
Liu, H., Zhao, H., & Sun, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.004 · Cited by 96 · see citing works
Self-citationGiannakoulas, N. C., Ntanasis‐Stathopoulos, I., & Terpos, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094462 · Cited by 88 · see citing works
Resistin: An inflammatory cytokine with multi-faceted roles in cancer
Sudan, S. K., Deshmukh, S. K., Poosarla, T., Holliday, N. P., Dyess, D. L., Singh, A. P., & Singh, S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188419 · Cited by 86 · see citing works
Resistin: A journey from metabolism to cancer
Deb, A., Deshmukh, B., Ramteke, P. L., Bhati, F. K., & Bhat, M. K. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101178 · Cited by 84 · see citing works
Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
Ria, R., & Vacca, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020613 · Cited by 65 · see citing works
Malvi, P., Chaube, B., Singh, S. V., Mohammad, N., Vijayakumar, M. V., Singh, S., Chouhan, S., & Bhat, M. K. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0176-5 · Cited by 63 · see citing works
Adipokines, adiposity, and bone marrow adipocytes: Dangerous accomplices in multiple myeloma
Morris, E., & Edwards, C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26884 · Cited by 60 · see citing works
Obesity and multiple myeloma: Emerging mechanisms and perspectives
Tentolouris, A., Ntanasis‐Stathopoulos, I., & Terpos, E. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.003 · Cited by 58 · see citing works
Qiu, L., Zhang, G., Yu, L., Wang, H., Jia, X., & Wang, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-30978-6 · Cited by 46 · see citing works
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies
Vallet, S., Filzmoser, J.-M., Pecherstorfer, M., & Podar, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040202 · Cited by 33 · see citing works
Fan, Y., Si, W., Ji, W., Wang, Z., Gao, Z., Tian, R., Song, W., Zhang, H., Niu, R., & Zhang, F. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1633-y · Cited by 42 · see citing works
Cheleschi, S., Giordano, N. G., Volpi, N., Tenti, S., Gallo, I., Meglio, M. D., Giannotti, S., & Fioravanti, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123909 · Cited by 36 · see citing works
Obesity and myeloma: Clinical and mechanistic contributions to disease progression
Marques-Mourlet, C., Iorio, R. D., Fairfield, H. E., & Reagan, M. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1118691 · Cited by 33 · see citing works
Bone marrow adiposity and multiple myeloma
Morris, E. V., & Edwards, C. M. (2018) · Bone · doi:10.1016/j.bone.2018.03.011 · Cited by 32 · see citing works
Lee, K., Wu, K., Yen, C., Chang, S., Chen, C., & Lu, Y.-C. (2022) · Pharmaceuticals · doi:10.3390/ph15070798 · Cited by 32 · see citing works
Zhang, M., Yan, L., Wang, G., & Jin, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27631 · Cited by 31 · see citing works
RetractedZhang, K., Li, M., Huang, H., Li, L., Yang, J., Feng, L., Gou, J., Jiang, M., Peng, L., Chen, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23253 · Cited by 30 · see citing works
Self-citationHuang, H., Li, T., Chen, M., Liu, F., Wu, H., Wang, J., Chen, J., & Li, X. (2018) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-018-0119-8 · Cited by 30 · see citing works
Bone Marrow Adipocytes: A Link between Obesity and Bone Cancer
Reagan, M. R., Fairfield, H. E., & Rosen, C. J. (2021) · Cancers · doi:10.3390/cancers13030364 · Cited by 28 · see citing works
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27 · see citing works
“Because of the importance of BM in cell growth and its expansion in the progression of MM, researchers have depicted that myeloma cells interact with BMSCs and the ECM, facilitating their growth and better survival and making them resistant to drugs [239].”
Sun, Y., Liu, W., Wang, C., Meng, Q., Liu, Z., Huo, X., Yang, X., Sun, P., Sun, H., Ma, X., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27141 · Cited by 26 · see citing works
Self-citationHelp or hindrance: The obesity paradox in cancer treatment response
O’Connell, F., & O'Sullivan, J. N. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.021 · Cited by 25 · see citing works
From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma
Fotiou, D., & Katodritou, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020327 · Cited by 24 · see citing works
Immunological roles for resistin and related adipokines in obesity-associated tumors
Zhang, J., Lu, E., Deng, L., Zhu, Y., Lu, X., Li, X., Li, F., Yan, Y., Han, J.-Y., Li, Y., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112911 · Cited by 25 · see citing works
Schwestermann, J., Bešše, A., Driessen, C., & Bešše, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.899272 · Cited by 25 · see citing works
Choa, R., Panaroni, C., Bhatia, R., & Raje, N. S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010822 · Cited by 23 · see citing works
Liu, H., Liu, L.-Y., & Rosen, C. J. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00594-9 · Cited by 27 · see citing works
Self-citationAllegra, A., Innao, V., Gerace, D. G., Allegra, A. G., Vaddinelli, D., Bianco, O., & Musolino, C. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.05.033 · Cited by 20 · see citing works
Cancer-associated adipocytes in the ovarian cancer microenvironment
Cai, Q. (2024) · American Journal of Cancer Research · doi:10.62347/xzri9189 · Cited by 21 · see citing works
Austin, M. J., Kalampalika, F., Cawthorn, W. P., & Patel, B. G. (2023) · British Journal of Haematology · doi:10.1111/bjh.18748 · Cited by 23 · see citing works
Obesity as a risk factor for multiple myeloma: insight on the role of adipokines
Tie, W., Ma, T., Yi, Z., Liu, J., Li, Y., Bai, J. Y., Li, L., & Zhang, L. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611338 · Cited by 19 · see citing works
Szymura, S. J., Wang, L., Zhang, T., Cha, S.-C., Song, J. Y., Dong, Z., Anderson, A., Oh, E., Lee, V., Wang, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50880-2 · Cited by 19 · see citing works
Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms
Manna, L., Gelsomino, L., Martino, E. A., Gentile, M., Andò, S., Bonofiglio, D., Giordano, C., Catalano, S., & Barone, I. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00644-w · Cited by 17 · see citing works
Liu, R., Gao, D., Lv, Y., Zhai, M., & He, A. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00939-2 · Cited by 15 · see citing works
Research advances of secretory proteins in malignant tumors
Zhang, N., Hao, J., Cai, Y., & Wang, M. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.01.12 · Cited by 12 · see citing works
Zhu, J., Wu, D., Zhao, C., Luo, M., Hamdy, R. C., Chua, B. H. L., Xu, X., & Miao, Z. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2326-5 · Cited by 12 · see citing works
Adipocyte–Tumor Interactions in the Bone Marrow Niche: Implications for Metastasis and Therapy
Dabaliz, A., Hakawati, M. N. A., Alrashdan, N., Alrashdan, S., Bakir, M., & Mohammad, K. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199781 · Cited by 11 · see citing works
Roles and mechanisms of adipokines in drug resistance of tumor cells
Li, Y., Yu, C., & Deng, W. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174019 · Cited by 11 · see citing works
Zhu, J., Wu, D., Zhao, C., Luo, M., Hamdy, R. C., Chua, B. H. L., Xu, X., & Miao, Z. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2359-9 · Cited by 9 · see citing works
Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
Abdalla, M. M. I. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i27.4271 · Cited by 8 · see citing works
Tang, H., Shu, M.-M., Dai, B., Xu, L., Dong, B., Gao, G., & Chen, X. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1413188 · Cited by 8 · see citing works
Myeloma and marrow adiposity: Unanswered questions and future directions
Morris, E. V., & Edwards, C. M. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101541 · Cited by 8 · see citing works
Critical Assessment of In Vitro and In Vivo Models to Study Marrow Adipose Tissue
Reagan, M. R. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00569-4 · Cited by 6 · see citing works
Resistin – A Plausible Therapeutic Target in the Pathogenesis of Psoriasis
Srikanth, M., & Rasool, M. (2023) · Immunological Investigations · doi:10.1080/08820139.2023.2288836 · Cited by 6 · see citing works
ABC-transporters and drug efflux in hematologic cancers
Lazarowski, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816434-1.00006-1 · Cited by 5 · see citing works
Effect of adipose tissue on the development of multiple myeloma
Stanisławowski, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10174-8 · Cited by 4 · see citing works
Ding, Y., Zhang, Y., Zhang, X., Shang, M., & Dong, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-74838-y · Cited by 3 · see citing works
High cholesterol increases myeloma tumour burden and promotes resistance to bortezomibPreprint
Gámez, B., Whipp, D., Rao, S. R., Morris, E. V., Park, Y. E., Kaya, Z., & Edwards, C. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.21.633916 · Cited by 3 · see citing works
Bone Marrow Adipocytes and Hematology: A Literature Review
Kriventsova, N. A., Shestopalov, A. M., & Tereshchenko, G. (2021) · International Journal of Biomedicine · doi:10.21103/article11(2)_ra2 · Cited by 2 · see citing works
Adipokines as Prognostic Biomarkers in Multiple Myeloma: A Case–Control Study
Al-Ali, N. O., Csige, D., Pinczés, L. I., Farkas, K., Rebenku, I., Domján, A., Panyi, G., Szekanecz, Z., Szűcs, G., Illés, Á., et al. (2025) · Medicina · doi:10.3390/medicina61112065 · Cited by 1 · see citing works
Cheng, F., Wang, Z., You, G., Liu, Y., He, J., & Yang, J. (2023) · Research Square · doi:10.21203/rs.3.rs-2535332/v1
Self-citationToomes, C. E., Best, G., Hollenberg, T., Turner, R., Bonder, C. S., & McClure, B. J. (2026) · Cancers · doi:10.3390/cancers18132050
Resistin in Tissue Remodeling and Fibrosis: A New Frontier
Ergun, B., Ahmed, M., & Lebeche, D. (2026) · Biomolecules · doi:10.3390/biom16081108
Roque, A. I., Paiva, A. A., Seiça, R. M. F., & Geraldes, C. (2026) · Cancers · doi:10.3390/cancers18193213
Malamos, P., Deligianni, E., Koutoulogenis, K., Terpos, E., & Souliotis, V. L. (2026) · DNA · doi:10.3390/dna6040055
- Authors
- Pang, J., Shi, Q., Liu, Z., He, J., Liu, H., Lin, P., Cui, J., & Yang, J.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- First Hospital of Jilin University (CN)
- Corresponding author
- Cui, Jiuwei
- Yang, Jing
- Venue
- Haematologica
- Published
- 2017-03-30
- Volume
- 102
- Issue
- 7
- Pages
- 1273-1280
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- PMC
- PMC5566043
- OpenAlex
- W2601031765
- Cited by
- 57
- References
- 35
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 8 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 2 · 2018: 12 · 2017: 4
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Haematologica (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Cancer Institute (R01CA193362, R01CA190863)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- resistin, multiple myeloma, multidrug resistance, chemoresistance, apoptosis, NF-κB signaling, PI3K/Akt signaling, ABC transporters, drug efflux, DNA methylation, DNMT1, DNMT3A, adipokines, bone marrow adipocytes, caspase cleavage
- MeSH terms
- Animals, Antineoplastic Agents, Disease Models, Animal, Humans, Multiple Myeloma, Gene Expression Regulation, Neoplastic, Apoptosis, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, DNA Methylation, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Resistin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
